​

TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TGTX Stock Forecast

TG Therapeutics (TGTX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $76.50, with a high of $83.00 and a low of $70.00. This represents a 37.84% increase from the last price of $55.50.

$10 $25 $40 $55 $70 $85 High: $83 Avg: $76.5 Low: $70 Last Closed Price: $55.5

TGTX Stock Rating

TG Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 1 Hold (7.69%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 1 11 0 Strong Sell Sell Hold Buy Strong Buy

TGTX Price Target Upside V Benchmarks

TypeNameUpside
StockTG Therapeutics37.84%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-24
Avg Price Target-$76.50$63.00
Last Closing Price$55.50$55.50$55.50
Upside/Downside-37.84%13.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26161-19
Jun, 26161-19
May, 26161-19
Apr, 26161-19
Mar, 26161-19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 22, 2026Jefferies$83.00$54.4052.57%49.55%
May 06, 2026H.C. Wainwright$70.00$39.7576.10%26.13%
Jan 15, 2026Goldman Sachs$39.00$29.5432.02%-29.73%
Oct 06, 2025Emily BodnarH.C. Wainwright$60.00$36.7163.44%8.11%
Nov 05, 2024Edward WhiteH.C. Wainwright$27.50$12.93112.68%-50.45%
Aug 06, 2024Corinne JenkinsGoldman Sachs$20.00$20.58-2.82%-63.96%
May 03, 2024Edward WhiteH.C. Wainwright$24.50$8.21198.42%-55.86%
Feb 07, 2023Cantor Fitzgerald$24.00$18.4829.87%-56.76%
Dec 30, 2022Evercore ISI$16.00$11.8335.25%-71.17%
Dec 29, 2022Edward WhiteH.C. Wainwright$12.00$4.23183.69%-78.38%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 22, 2026JefferiesBuyBuyhold
May 06, 2026H.C. WainwrightBuyBuyhold
Jan 15, 2026Goldman SachsNeutralNeutralhold
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 17, 2025B. RileyBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 29, 2024Cowen & Co.Buyinitialise
Oct 24, 2024B. RileyBuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Goldman SachsNeutralNeutralhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-1.46$0.09$0.16$3.10---
Avg Forecast$-2.56$-1.34$-0.01$0.11$1.00$1.78$2.86$3.71
High Forecast$-2.01$-1.17-$0.16$1.52$2.24$3.33$3.85
Low Forecast$-3.06$-1.55$-0.02$0.05$0.44$0.97$2.53$3.42
Surprise %2.73%8.96%-1000.00%45.45%210.00%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.69M$2.79M$233.66M$329.00M$616.29M---
Avg Forecast$7.01M$4.27M$231.08M$320.87M$534.67M$748.29M$997.20M$1.26B
High Forecast$8.07M$4.78M$231.20M$326.08M$535.99M$748.31M$1.00B$1.29B
Low Forecast$5.85M$3.84M$230.90M$315.78M$533.35M$748.27M$991.12M$1.18B
Surprise %-4.59%-34.74%1.12%2.54%15.27%---

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-348.10M$-223.81M$12.67M$23.38M$447.18M---
Avg Forecast$-380.37M$-199.66M$-1.70M$15.43M$168.38M$273.41M$448.46M$550.22M
High Forecast$-298.35M$-173.92M$-424.17K$23.60M$226.28M$332.62M$493.91M$571.30M
Low Forecast$-454.86M$-230.73M$-2.97M$7.26M$65.27M$144.20M$375.07M$507.85M
Surprise %-8.48%12.10%-846.87%51.56%165.57%---

TGTX Forecast FAQ

Is TG Therapeutics stock a buy?

TG Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that TG Therapeutics is a favorable investment for most analysts.

What is TG Therapeutics's price target?

TG Therapeutics's price target, set by 13 Wall Street analysts, averages $76.5 over the next 12 months. The price target range spans from $70 at the low end to $83 at the high end, suggesting a potential 37.84% change from the previous closing price of $55.5.

How does TG Therapeutics stock forecast compare to its benchmarks?

TG Therapeutics's stock forecast shows a 37.84% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for TG Therapeutics over the past three months?

  • July 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • June 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • May 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.

What is TG Therapeutics’s EPS forecast?

TG Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $1.78, marking a -42.58% decrease from the reported $3.1 in 2025. Estimates for the following years are $2.86 in 2027, and $3.71 in 2028.

What is TG Therapeutics’s revenue forecast?

TG Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $748.29M, reflecting a 21.42% increase from the reported $616.29M in 2025. The forecast for 2027 is $997.2M, and $1.26B for 2028.

What is TG Therapeutics’s net income forecast?

TG Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $273.41M, representing a -38.86% decrease from the reported $447.18M in 2025. Projections indicate $448.46M in 2027, and $550.22M in 2028.